“It is of critical importance to give individuals with Down Syndrom access to high-level research on potential outcome measures for treatment trials and finally to treatment trials to prevent the development of symptomatic Alzheimer Disease”, explains Johannes Levin, leader of the neurodegenerative diseases group of the Department of Neurology at the Ludwig-Maximilians Universität München and the German Center for Neurodegenerative Diseases (DZNE). The research team includes researchers from the following other universities: the Washington University School of Medicine, King’s College London, Hospital Sant Pau in Barcelona, University of Gothenburg in Sweden, and Instituto Fleni in Buenos Aires.

More information about the grant and study can be found on the website of the Washington University School of Medicine in St. Louis: https://medicine.wustl.edu/news/cognitive-function-in-down-syndrome-associated-alzheimers-focus-of-grant/